Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Company profile
Website
CEO
Tim M. Mayleben
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
383419139
Latest filings (excl ownership)
15-15D
Suspension of duty to report
11 Feb 04
8-K
Changes in control of registrant
11 Feb 04
SC TO-T/A
Third party tender offer statement (amended)
5 Feb 04
8-K
Financial statements and exhibits
23 Jan 04
SC TO-T/A
Third party tender offer statement (amended)
23 Jan 04
SC 14D9/A
Tender offer solicitation (amended)
21 Jan 04
SC 14D9/A
Tender offer solicitation (amended)
8 Jan 04
SC 14D9
Tender offer solicitation
7 Jan 04
SC TO-T
Third party tender offer statement
7 Jan 04
8-K
Other events
23 Dec 03
Latest ownership filings
SC 13G
PLATINUM INVESTMENT MANAGEMENT LTD
10 Feb 22
SC 13G/A
BB BIOTECH AG
27 May 21
SC 13G/A
Esperion Therapeutics Inc/mi
14 Feb 20
SC 13G/A
Esperion Therapeutics Inc/mi
14 Feb 19
SC 13G/A
Esperion Therapeutics Inc/mi
13 Feb 19
SC 13G/A
Esperion Therapeutics Inc/mi
14 Feb 18
SC 13G/A
Esperion Therapeutics Inc/mi
14 Feb 17
SC 13G/A
Esperion Therapeutics Inc/mi
14 Feb 17
SC 13G
Esperion Therapeutics Inc/mi
27 Sep 16